Premier Alternatives

Stipple Bio

Cambridge, MA · Founded 2022 · Privately Held (backing)

Operator of a biotechnology company intended to unlock cellular profiling and target discovery. Stipple Bio is based in Cambridge, MA and was founded in 2022. It was valued at $2.2 billion at its early-stage round in Apr 2026, the last priced event on record. It has raised $121 million across 2 recorded rounds; the latest was a $65.1 million later-stage round in Mar 2026.

PMV mark · valuation
$2.2B
Oct 2026
Priced at
its early-stage round
Apr 2026
Total raised
$121.5M
Last round
Later Stage VC
Mar 2026

Stipple Bio key facts

as of Oct 2026
  • Operator of a biotechnology company intended to unlock cellular profiling and target discovery.
  • Stipple Bio is valued at approximately $2.2B as of Oct 2026, set at its early-stage round, Apr 2026; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $121.5M across 2 recorded rounds; the latest was Later Stage VC ($65.1M) in Mar 2026.
  • Notable investors include Andreessen Horowitz, RA Capital Management, GV, Emerson Collective, Magnetic Ventures — 10 tracked in total.
  • Stipple Bio has filed 1 Form D with the SEC, most recently Dec 2024 ($9.5M sold to 1 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$2.2B

Valued at $2.2B at its early-stage round, Apr 2026. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Stipple Bio with a free account
  • ·Watch Stipple Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Stipple Bio funding rounds

2 rounds
Mar 2026Later Stage VC$65.1MSEC filing▮
Dec 2024Early Stage VC$9.5MSEC filing▮
Full funding history →

Stipple Bio valuation

Stipple Bio was valued at $2.2 billion at its early-stage round in Apr 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Stipple Bio raised?

Stipple Bio has raised $121 million in total; 2 of its rounds are on record. The largest on record was a $9.5 million early-stage round in Dec 2024; the most recent was a $65.1 million later-stage round in Mar 2026.

Stipple Bio has filed 1 Form D with the SEC, most recently in Dec 2024 ($9.5 million sold to 1 investor).

Stipple Bio investors

10 investors are on record for Stipple Bio, including Andreessen Horowitz, RA Capital Management, GV and Emerson Collective. By type, the record holds 3 venture capital firms, 1 asset manager and 1 private equity firm. The later-stage round in Mar 2026 drew 15 investors.

About Stipple Bio

Operator of a biotechnology company intended to unlock cellular profiling and target discovery. The company offers epitope-level resolution technology for single-cell profiling and allows the identification of novel therapeutic targets and the development of precision therapies, enabling users with therapies for a wide range of solid and hematologic malignancies.

Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2022
Employees
7
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.